

PROGRAM OVERVIEW

WHO SHOULD ATTEND

This program is recommended for physicians with experience and/or interest in treating opioid dependence. This program is also recommended for primary care, psychiatric, HIV and addiction medicine physicians.

CONTINUING MEDICAL EDUCATION CREDIT

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The American Society of Addiction Medicine (ASAM) designates this continuing medical education activity for up to 8 hours in Category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by an unrestricted continuing medical education grant provided by Reckitt Benckiser.

PROGRAM GOALS & OBJECTIVES

- After participating in this course, participants should be better able to describe:
- The prerequisites for a physician to begin to prescribing buprenorphine in office-based practice
 - The clinically relevant pharmacological characteristics of buprenorphine
 - Factors to consider in determining if a patient is an appropriate candidate for office-based treatment
 - Induction, maintenance, and detoxification protocols
 - Strategies for integrating psychosocial care with office-based pharmacological treatment
 - Treatment strategies for management of chronic and acute pain in patients in maintenance treatment for opioid dependence
 - The appropriate monitoring of patients with HIV and/or HCV who are receiving buprenorphine

The Drug Addiction Treatment Act of 2000 (PL106-310, Section 3502) permits physicians who are trained or experienced in opioid addiction treatment to obtain waivers to prescribe certain narcotic drugs in Schedule III, IV, or V of the Controlled Substances Act, in their office practices or in a clinic setting, for the treatment of opioid dependence. Both buprenorphine sublingual and the combination of buprenorphine/naloxone are approved by FDA for use in detoxification and maintenance treatment of opioid dependence.

Physicians are qualified if they are certified in Addiction Medicine or Addiction Psychiatry. As part of the requirements to obtain the waiver, physicians not otherwise qualified must complete not less than 8 hours of training. Physicians who complete this 8-hour course will meet the training qualification under the new law and will receive a certificate of attendance suitable to send to the Secretary of HHS along with the request for the waiver. If you give ASAM permission to do so, ASAM will report your name directly to the Secretary of HHS within 4 weeks of the program, if you have attended the full 8 hours, eliminating the need for you to send the certificate of attendance.

Because ASAM will be called upon to confirm that participants have attended a full 8 hours, you must bring a photo identification to show as part of the sign-in process; you must confirm your attendance with your signature at the beginning of both the morning and the afternoon sessions; and you must sign out at the conclusion of the program.

Certificates of attendance will be mailed to you within 4 weeks of the program. Note that latecomers will not be eligible for a certificate of attendance if ASAM cannot confirm 8 hours of attendance.



Sponsored by:
American Society of Addiction Medicine (ASAM)
Supporting Organization:
Illinois Society of Addiction Medicine (ISAM)

BUPRENORPHINE AND
OFFICE-BASED TREATMENT
OF OPIOID
DEPENDENCE



SATURDAY, JUNE 18, 2005
7:00 AM -5:30 PM

WYNDHAM O'HARE HOTEL
6810 NORTH MANNHEIM ROAD
ROSEMONT, IL 60018
PHONE: 847-297-1234

Physicians who complete this course will be eligible to request a waiver to practice medication-assisted addiction therapy with Buprenorphine, for the treatment of opioid dependence.

www.samhsa.gov | www.buprenorphine.samhsa.gov
www.asam.org

BUPRENORPHINE AND
OFFICE-BASED TREATMENT
OF OPIOID
DEPENDENCE

PROGRAM REGISTRATION

PLEASE COMPLETE FORM ON REVERSE
AND SUBMIT BY MAIL OR FAX



American Society of Addiction Medicine
Meeting Producer
P.O. Box 378
Sea Girt, NJ 08750

PROGRAM REGISTRATION

PLEASE REGISTER AT
WWW.DOCOPTIN.COM

- Registration Fees
- \$100 ASAM members
 - \$125 non-ASAM members
 - \$75 non-Physicians
 - \$0 Residents

Pre-registration is recommended, as space is limited and registrations are accepted on a first come, first served basis.

Cancellation Policy: Requests must be received via Fax, Email or Post-marked 14 calendar days or more prior to the program date. Fifty percent (50%) of the registration fee will be refunded. Send requests to: Meeting Producer, Fax: 732-751-2717; Email: optin@dsuccess.com; Mail: PO Box 378, Sea Girt, NJ 08750.

ALTERNATE REGISTRATION METHODS
CALL 888-Doc-Opt-In (888-362-6784)

OR COMPLETE THIS FORM AND SUBMIT BY MAIL OR FAX

Make all checks payable to: **ASAM**
Mail: P.O. BOX 378
SEA GIRT, NJ 08750
FAX: 732-751-2717

☐ \$100 ASAM ☐ \$125 non-ASAM ☐ \$75 non-Physician ☐ \$0 Residents

Full Name _____

☐ DO ☐ MD ☐ Resident

ASAM# _____

Address _____

City _____ State _____ Zip _____

Phone _____ Fax _____

Email (Print Clearly) _____

To receive an electronic registration confirmation, please fill in email address

Charge to my Visa ☐ or MasterCard ☐ (check boxes)

Card # _____ Exp. Date _____

Signature _____

ASAM /CHICAGO061805

PROGRAM FACULTY

PETER FRIEDMAN, MD

Associate Professor of Medicine & Community Health
Brown Medical School

MARTIN C. DOOT, MD

Medical Director, Advocate Addiction Treatment Program

SARZ MAXWELL, MD, FASAM

President, ISAM
Medical Director, Chicago Recovery Alliance

JEFFREY D. ROTH, MD, FASAM

Editor, Journal of Groups in Addiction and Recovery

ABDEL R. FAHMY, MD

Associate Medical Director
Access Community Health Network

To fully complete the form necessary to prescribe buprenorphine, please bring your DEA number and your group or solo practice Tax ID employer identification number, as well as the names and DEA numbers of all other physicians in your practice.

TOPICS TO BE DISCUSSED

Overview of Opioid Dependence

Rationale for Opioid Agonist Treatment

Legislative Changes Allowing Office-Based Treatment of Opioid Dependence, Including the Drug Addiction Treatment Act of 2000

General Opioid Pharmacology

Pharmacology of Buprenorphine and Buprenorphine/Naloxone

Efficacy and Safety of Buprenorphine/Naloxone

Clinical Use of Buprenorphine and Buprenorphine/Naloxone, Including Induction, Maintenance, and Pharmacologic Withdrawal

Patient Assessment and Selection

Office Procedures and Logistics

Psychiatric Co-Morbidity in Opioid Dependent Patients

Medical Co-Morbidity in Opioid Dependent Patients

The Role of Psychosocial Counseling in the Treatment of Opioid Dependence

Special Treatment Populations, Including the Management of Patients who Develop Pain while Receiving Buprenorphine/ Naloxone, Pregnancy and Adolescents

7:00 AM - 8:00 AM Registration and Mandatory Sign-In

8:00 AM - 5:30 PM Program, Including Lunch

5:30 PM Mandatory Sign-Out

DIRECTIONS

1. ORD - O`Hare International AirportDistance : 1.5 miles

DirectionsExit airport to Mannheim North. Proceed 2 miles, Hotel on left.

Transportation Costs:

Type	Cost (One Way)	Cost (Round Trip)
Taxi	\$8.00	\$16.00

